Myelodysplastic Syndromes (MDS)
Original Publication Date
Article Source
External Web Content
June 2, 2022 - Omidubicel is a first-in-class, advanced NAM-enabled stem cell therapy candidate being evaluated as the first potential allogeneic advanced cell therapy donor source for patients with blood cancers in need of a transplant – - Omidubicel has Orphan Drug Designation…
MDS to AML - 2022 San Antonio Patient & Family Virtual Conference
Topic(s)
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
Presenter(s)
Amer Zeidan, MBBS
In this conference session, Dr. Amer Zeidan, MD discusses understanding the management options for higher risk MDS, the evolution of MDS to AML and more.
MDS/MPN Overlap - 2022 San Antonio Patient & Family Virtual Conference
Topic(s)
Myelodysplastic Syndromes (MDS)
Presenter(s)
Ruben Mesa, MD, FACP
In this conference session, Dr. Ruben Mesa, MD discusses the different features between MDS and MPN and their overlap syndromes.
Living With Bone Marrow Failure Diseases - 2022 San Antonio Patient & Family Virtual Conference
Topic(s)
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Living Well with Bone Marrow Failure
Managing Your Treatment
Myelodysplastic Syndromes (MDS)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Related Bone Marrow Failure Diseases and Malignancies
Presenter(s)
Krisstina Gowin, DO
In this conference session, Dr. Krisstina Gowin DO discusses best practices when living with bone marrow failure diseases.
The Rise of the Expert Patient in Cancer: From Backseat Passenger to Co-navigator
Original Publication Date
Article Source
External Web Content
PURPOSE: Patients who have cancer have leveraged the Internet to gain a better understanding of their disease and connect across geographic boundaries with others facing the same challenges. Online cancer communities have developed into resources that highlight new research and…
Firas El Chaer, MD
Institution
University of Virginia
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
Firas El Chaer, MD, is an assistant professor of medicine who specializes in hematology and oncology. His clinical areas of interest are acute leukemia, chronic leukemia, myelodysplastic syndrome, myeloproliferative disorders, aplastic anemia, clonal hematopoiesis and blood disorders. His research focuses on improving outcomes for acute leukemia in adults by focusing on targeted therapies and overcoming resistance mechanisms. Dr. El Chaer attended medical school at the University of Balamand in Beirut, Lebanon, and completed his internal medicine residency at the Icahn School of Medicine at
Sabatolimab
Sabatolimab Sabatolimab: Sabatolimab (MBG453) is a novel immuno-myeloid therapy that binds to TIM-3 on immune cells, facilitating antileukemic immune activation and phagocytic killing of leukem
Decitabine and Cedazuridine
INQOVI® for adult patients with MDS or CMML who are intermediate-1, intermediate-2, and high-risk IPSS groups. It is a prescribed oral tablet combination of decitabine and cedazurine approved by the FDA for adult patients with myelodysplastic syndromes (MDS) and patients with chronic myelomonocytic leukemia (CMML) including:
Seeing Cancer From All Sides: Richard M. Stone Is Giant of Cancer Care in Leukemia
Original Publication Date
Article Source
External Web Content
Driven by his mother’s advice and his father’s memory, Richard M. Stone, MD, rose to become a global leader in leukemia care and research. Growing up, Richard M. Stone, MD, thought he was going to be an attorney like his father, but his direction in life changed when he was 15…
Anand Karnad, MD
Institution
Mays Cancer Center at UT Health San Antonio MD Anderson
Physician Status
accepting new patients
Primary Disease Area of Focus
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
Dr. Anand Karnad received his medical degree from Madras Medical College at the University of Madras (Chennai), in India. Dr. Karnad is Chief, Division of Hematology-Oncology at the Department of Medicine, and UT Health San Antonio MD Anderson Cancer Center and has been Professor of Medicine here since 2004. He has been an active investigator for the National Cancer Institute Clinical Trials for two decades, including trials designed to prevent and treat a range of cancers. He is principal investigator for the National Clinical Trials System (NCTN) SWOG trials at the Cancer Center. He is
